Three returns, one ruler
AI value arrives in three different currencies. Most programmes measure all three with the ruler built for one of them.

The argument in brief
- AI value comes in three returns, not one. Gartner separates business cases that Defend, Extend and Upend, yielding a return on employees, a return on investment and a return on the future. They run in parallel, not as a ladder.
- Only the middle one behaves like an investment case. In a peer reviewed study of 5,179 support agents, a re-engineered process moved an owned metric, issues resolved per hour, by 14 percent on average and 34 percent for novices.
- The other two are being judged on its terms. 89 percent of nearly 6,000 executives report no productivity impact from AI over three years, yet the same executives expect 1.4 percent over the next three. Value judged before it can show is value cancelled.
- That is the delay trap: asking an employee or future return to pay back on an investment timeline, and killing it at the first quarterly review.
- Named cases show each return in practice. UBS and The Permanente Medical Group report users and hours, the currency of an employee return. DBS and Klarna report money, and Klarna shows what happens when the only metric is cost. Medtronic's GI Genius shows a future return justified by clearance and trial milestones, not payback.
- The fix is governance, not tooling. Name the return at the Fund gate, judge each return on its own measures at the Scale gate, and run each from its own funding pool. A five question diagnostic at the end tells you which return an initiative is chasing.
Every AI investment committee eventually asks the same question: what is the return? It is the right question asked in the wrong singular. AI produces three different kinds of value, and only one of them answers to a payback period.
The other two are real, but they arrive in a different currency and on a different clock. Measure them with the investment ruler and they look like failures, right up until the moment they are cancelled. This insight sets out the three returns, what the 2026 evidence says about each, where the measurement goes wrong, and how to govern a portfolio that runs all three at once.
It is a companion to The number nobody decks, which asked how far the evidence of AI value has travelled, from the user to the P&L. This piece asks the question that comes before it: what kind of value is it in the first place?
1.Three business cases, three currencies
Gartner's framework, The 3 Business Cases of Generative AI Value (Nate Suda and Hung LeHong, January 2025), argues that AI outcomes range from everyday to game changing and cannot be described by a single currency of value. It separates three business case types. Defend cases yield employee returns. Extend cases create a return on investment. Upend cases create a return on the future. We abbreviate them here as ROE, ROI and ROF.
The important word is parallel. These are not three stages that an initiative climbs through. A healthy portfolio runs all three at the same time, for different reasons, measured in different ways.
Exhibit 1
Three returns, and the ruler that fits each
| Return | Business case | What it buys | Measure it on | Fund it like |
|---|---|---|---|---|
| Return on employee | Defend | Parity: people work faster and decide better | Active use, depth of use, time saved, quality and error rates | An operating cost |
| Return on investment | Extend | A re-engineered process that produces more for less | An owned business metric with a baseline: cost per case, cycle time, margin, loss rate | An investment, with payback |
| Return on the future | Upend | A new position: a market, product or model the firm could not reach before | Strategic milestones, learning velocity, the value of keeping the option open | A venture |
Business cases and returns: Gartner, The 3 Business Cases of Generative AI Value, 2025. Measures and funding: Auron Advisory synthesis.
2.Return on employee: the Defend case
The return on employee is the value of augmenting individual people: a relationship manager who drafts client correspondence in half the time, an underwriter who reads a policy file faster, an analyst who spends less of the week summarising. It is the most common case and the most diffuse. The value is spread thinly across thousands of working days rather than concentrated in one line of the accounts.
Adoption is now broad but uneven. Eurostat reports that 20 percent of EU enterprises with ten or more employees used at least one AI technology in 2025, rising to 55 percent of large enterprises against 17 percent of small ones. In a survey of nearly 6,000 executives across the US, UK, Germany and Australia, 69 percent of firms actively use AI, and executives who use it personally average about 1.5 hours a week. McKinsey's 2026 survey finds that 80 percent of its 1,719 respondents say AI has improved their productivity.
Wide, felt and shallow is exactly the profile of a return on employee. It is a real return. It is simply not a financial one yet, and demanding that it become one at the first review misreads what was bought. The leading indicator here is not payback. It is whether use is active, repeated and deepening, because without that there is no return of any kind.
In practice · Financial services · UBS
Early in 2025 UBS activated 55,000 Microsoft 365 Copilot licences. By August its in-house assistant, Red, was in use by 52,000 employees, and staff sent 8 million prompts across the bank's generative AI tools in the second quarter alone, about four times the level at the end of 2024. The stated target for AI-supported development tools is a 15 percent efficiency gain.
Notice what is reported: licences, users and prompts. That is the right instrument for a Defend case. It is not a P&L line, and nobody should ask it to be one yet.
Source: Netzwoche, 26 August 2025, reporting UBS figures. Licences activated are not active users, and the 15 percent is a target, not a result.
In practice · Healthcare · The Permanente Medical Group
On the clinical side, The Permanente Medical Group rolled out an ambient AI scribe that drafts visit notes. Over 63 weeks to December 2024, 7,260 physicians used it across 2,576,627 patient encounters, saving an estimated 15,791 hours of documentation time.
Again the currency is time returned to clinicians, which is what a MedTech or health system buyer of such a tool should be judging first.
Source: American Medical Association, June 2025, reporting the organisation's own published analysis. Hours saved are estimated by the organisation.
3.Return on investment: the Extend case
The return on investment comes from re-engineering a specific process with a metric that already exists and already has an owner. It is the only one of the three that behaves like a conventional investment case, which makes it the easiest to fund and the easiest to over weight.
The clearest evidence comes from a single re-engineered process. Brynjolfsson, Li and Raymond, in The Quarterly Journal of Economics, studied a generative AI assistant rolled out to 5,179 customer support agents.
Exhibit 2
One process, one owned metric: issues resolved per hour after an AI assistant
Source: Brynjolfsson, Li and Raymond, Generative AI at Work, The Quarterly Journal of Economics 140(2), 2025. 5,179 agents at one firm. Bars drawn to a common scale; the experienced group is shown as minimal because the paper reports it that way rather than as a point estimate.
Two things make this an Extend case rather than a Defend one. The process had a metric before the AI arrived, and the change was measured on it. That is what lets a return on investment be proven. It also shows where the value concentrates: in compressing the gap between novice and expert, which is a design choice about who the tool is for.
Extend cases fail differently. The risk is not that value goes unmeasured, but that credit is claimed against a metric the initiative did not move. The executive survey from the Federal Reserve Bank of Atlanta shows how wide that gap can run: executives reported a 1.8 percent labour productivity gain from AI for 2025, while their own revenue and employment figures implied 0.6 percent. A return on investment has to be read in the revenue-implied number, not in the survey.
In practice · Financial services · DBS
DBS reports more than 430 AI use cases and over 2,000 models delivering economic value of approximately SGD 1 billion in 2025. That is what an Extend portfolio looks like when a bank decides to count it: use cases tied to outcomes it already tracks, added up across the firm.
Source: DBS Annual Report 2025, letter from the Chairman and CEO. The bank does not publish how economic value is measured, so treat the figure as its own account.
In practice · Financial services · Klarna
In February 2024 Klarna said its AI assistant had handled 2.3 million conversations in its first four weeks, two thirds of its customer service chats, the equivalent workload of 700 full-time agents, with resolution in under 2 minutes against 11 before. It expected a 40 million US dollar profit improvement in 2024.
By May 2025 its CEO said cost had been "a too predominant evaluation factor" and that quality had suffered, and the company began hiring so that customers could reach a human. The return was real on the metric chosen. The case still had to be reopened, because the metric did not include what customers experienced. An Extend case needs its owned metric and a guardrail metric beside it.
Sources: Tech.eu, 28 February 2024, and eMarketer, 8 May 2025, both reporting Klarna's own figures and statements.
In practice · MedTech · Siemens Healthineers
Siemens Healthineers says its Deep Resolve image reconstruction can accelerate brain MRI scans by up to 70 percent. For a hospital, that is a classic Extend case: the same scanner and the same staff producing more examinations a day, measured on a metric radiology already owns, slots per scanner.
Source: Siemens Healthineers press release, 13 July 2022. A manufacturer claim based on data on file. Faster scans become a return only if the freed slots are filled.
4.Return on the future: the Upend case
The return on the future is a strategic bet: a new market, a new product, or a public facing model that changes the firm's position rather than its cost base. For a bank it might be an advice service delivered largely by AI to a segment that was never profitable to serve. For an insurer, distribution through partner platforms. The right question is not what the payback is, but what position the bet buys and what it costs to keep the option open.
This is where the evidence is thinnest, and that is itself informative. In McKinsey's 2026 survey, 6 percent of respondents attribute 5 percent or more of EBIT to AI, unchanged from the year before. The top performers among them report pursuing growth or innovation alongside efficiency, and nearly three quarters report fundamentally redesigning workflows, against about a quarter of everyone else.
That tells us what the firms furthest along say they do. It does not measure a return on the future as a realised outcome, and no source we hold does. The honest position is that this return is governed by intent and milestones today, and that any number offered as its payback should be treated with suspicion.
In practice · MedTech · Medtronic and Cosmo, GI Genius
The clearest Upend case in MedTech is a product, not a programme. GI Genius, developed by Cosmo Pharmaceuticals and distributed worldwide by Medtronic, received FDA De Novo clearance in April 2021, described by Medtronic as the first commercially available computer-aided detection system for colorectal polyps. In its randomised trial of 685 patients at three Italian centres, the adenoma detection rate was 54.8 percent with the system against 40.4 percent without, with no significant difference in withdrawal time.
The milestones that justified the bet were a new product category, a regulatory clearance and a randomised trial. None of them is a payback figure, and the financial return has not been disclosed. In financial services we found no Upend case with a disclosed outcome, which matches the survey evidence above.
Sources: Repici and others, Gastroenterology 159(2), 2020; Medtronic announcement of FDA De Novo clearance, April 2021.
5.The delay trap
The failure that the three returns are designed to prevent has a simple mechanism. An initiative that is really a return on employee, or a return on the future, is approved through the investment process because that is the only process there is. It is then reviewed against a payback curve it was never going to follow. It shows nothing on the P&L by the second quarter, and it is cut.
The 2026 data shows how much value currently sits on that slower clock. Across the four country panel, 89 percent of executives report no productivity impact from AI over the past three years, yet the same executives expect AI to raise labour productivity by 1.4 percent over the next three. Whatever one makes of the forecast, the value they describe is expected later than it is being judged.
European firm data points the same way. The Bank for International Settlements finds AI adoption associated with a one-off productivity level shift of about 4 percent among non-financial firms, an effect amplified most by investment in training. Training is a cost incurred now for a return that arrives later, which is precisely the kind of spend a payback gate is built to reject.
Judged on an investment timeline, almost every employee or future return looks like a failure, right up until it is cancelled.
6.Three gates, three rulers
The fix is a governance discipline, not a better model or a better survey. Auron applies it at the three gates every initiative passes through.
- At the Fund gate, name the return before the number. Every initiative is tagged ROE, ROI or ROF, and Defend, Extend or Upend, before a business case is written. The tag decides which ruler applies for the rest of its life.
- At the Scale gate, judge each return on its own measures. A return on employee scales on active and deepening use. A return on investment scales only if its owned metric has moved against baseline at full volume. A return on the future scales when its milestones are hit and the option is still worth holding.
- At the Run gate, keep separate funding pools. Employee returns are run as operating cost, investment returns are measured net of the AI spend that produces them, and future returns are held to a venture budget with a defined exit. The investment lens never sets the bar for the other two.
Exhibit 3
One rule per return, per gate
| Gate | Return on employee | Return on investment | Return on the future |
|---|---|---|---|
| Fund | Named users, current baseline of time and quality | Owned metric, baseline, owner and date written into the case | Strategic thesis, milestones, kill criteria |
| Scale | Active and repeated use rising, quality holding | Metric moved at full volume, visible in revenue-implied terms | Milestones hit, option still worth holding |
| Run | Operating cost, reviewed on depth of use | Return measured net of AI spend | Venture budget, defined exit |
Framework: Auron Advisory.
7.Which return is this initiative chasing?
Before any AI business case is written, five questions settle which ruler it should be held to. Answer them for the initiative, not for the technology.
Choose one answer per question. The tally updates as you go, and the verdict appears once all five are answered.
8.The limits of this evidence
- The three-way split is a governance discipline to impose, not a description of how firms currently measure AI. No source we hold shows firms separating the three returns in practice.
- Only the support study measures a return directly, in one firm and on an early model. The BIS result is derived from firm accounts. Every other figure here is reported by executives or respondents.
- No source measures a return on the future as a realised outcome. The evidence for it is about intent and practice among the firms furthest along.
- The executive surveys are anchored in the US, UK, Germany and Australia, and the European firm data excludes financial firms and contains no Swiss firms. Read across to Swiss banks, insurers and MedTech firms is a hypothesis to test, not a finding.
- The named cases rely on what each organisation has published or told the press. Only the GI Genius trial is independently peer reviewed. The bank, insurer and asset manager scenarios in the text are illustrations, not documented cases.
Before the next AI business case reaches your committee, ask which of the three returns it is chasing. Then ask whether the ruler you are about to hold it to was built for that return.
Auron Advisory is formed to build the intelligent enterprise: organisations where AI and disruptive technologies not only increase productivity but open new markets and materially improve the ones already there.
Sources
[1] Suda and LeHong. The 3 Business Cases of Generative AI Value. Gartner, 6 January 2025. Subscription research; the mapping of Defend, Extend and Upend to employee returns, return on investment and return on the future is as reproduced by Lumen, with Gartner's permission.
[2] Eurostat. Use of artificial intelligence in enterprises. Statistics Explained, data extracted December 2025. EU enterprises with ten or more employees, reference year 2025. Measures adoption, not return.
[3] Yotzov, Barrero, Bloom, Bunn, Davis and others. Firm Data on AI. NBER Working Paper 34836, February 2026, revised March 2026. Nearly 6,000 senior executives in the US, UK, Germany and Australia, surveyed November 2025 to January 2026. Working paper.
[4] Tinkoff, Van der Veken and Chui, with Balakrishnan. The state of AI in 2026: On the road to ROI. McKinsey & Company, August 2026. 1,719 participants in 97 nations, fielded 4 May to 8 June 2026. Opt-in survey; figures are respondents' own reports.
[5] Brynjolfsson, Li and Raymond. Generative AI at Work. The Quarterly Journal of Economics 140(2), pp. 889 to 942, 2025. 5,179 customer support agents at one firm. Peer reviewed.
[6] Baslandze, Edwards, Graham, McClure, Sparks, Meyer, Waddell and Weitz. Artificial Intelligence, Productivity, and the Workforce: Evidence from Corporate Executives. Federal Reserve Bank of Atlanta Working Paper 2026-4, 25 March 2026. Nearly 750 executives, mostly CFOs. Working paper.
[7] Aldasoro, Gambacorta, Pal, Revoltella, Weiss and Wolski. AI adoption, productivity and employment: evidence from European firms. BIS Working Paper 1325, 23 January 2026. Roughly 12,000 EU non-financial firms matched to firm accounts. Excludes financial firms; no Swiss firms.
[8] Netzwoche. UBS setzt im grossen Stil auf generative KI. 26 August 2025. Trade press reporting UBS figures.
[9] American Medical Association. AI scribes save 15,000 hours, and restore the human side of medicine. June 2025. Reports The Permanente Medical Group's own published analysis.
[10] DBS Bank. Annual Report 2025, letter from the Chairman and CEO. Company reported; measurement method not published.
[11] Tech.eu. Klarna AI assistant does the work of 700 people. 28 February 2024. And eMarketer, Klarna backtracks AI customer service plans, 8 May 2025. Company figures.
[12] Siemens Healthineers. Deep Resolve press release. 13 July 2022. Manufacturer claim.
[13] Repici and others. Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial. Gastroenterology 159(2), 2020. 685 patients, three centres in Italy. Peer reviewed.
[14] Medtronic. FDA grants De Novo clearance for GI Genius. April 2021. Company announcement.
This is the kind of problem we work on.
If your AI programme is stuck between pilot and production, a 30-minute call will tell you honestly whether it's set up to reach it — no pitch.
Book a discovery call →